|Positive WB detected in||Jurkat cells, K-562 cells, human liver tissue, human brain tissue, HEK-293T cells, A431 cells, mouse spleen tissue, Raji cells, HL-60 cells, MCF-7 cells, HeLa cells|
|Positive IP detected in||Raji cells|
|Positive IHC detected in||human tonsillitis tissue, human cervical cancer tissue, human lung cancer tissue, human pancreas tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||MCF-7 cells|
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
16225-1-AP targets MCL1 in WB, IP, IHC, IF,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||MCL1 fusion protein Ag10397|
|Full Name||myeloid cell leukemia sequence 1 (BCL2-related)|
|Calculated molecular weight||350 aa, 37 kDa|
|Observed molecular weight||35-40 kDa|
|GenBank accession number||BC107735|
|Gene ID (NCBI)||4170|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumour malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target. MCL-1 can be alternatively spliced into a long form (MCL-1L, 40 kDa) or a short form (MCL-1S, 30 kDa). (PMID: 15467463, PMID: 15147382)
|Product Specific Protocols|
|WB protocol for MCL1 antibody 16225-1-AP||Download protocol|
|IHC protocol for MCL1 antibody 16225-1-AP||Download protocol|
|IF protocol for MCL1 antibody 16225-1-AP||Download protocol|
|IP protocol for MCL1 antibody 16225-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.
J Cell Mol Med
MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT-β-catenin pathways.
Oxymatrine protects neonatal rat against hypoxic-ischemic brain damage via PI3K/Akt/GSK3β pathway.
Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Bosn J Basic Med Sci
CircRNA_014511 affects the radiosensitivity of bone marrow mesenchymal stem cells by binding to miR-29b-2-5p.
The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis.